The GEOMETRY duo-1 trial (NCT02468661), a phase Ib/II study focusing on the efficacy of capmatinib plus erlotinib vs. platinum plus pemetrexed in EGFR-TKI-treated NSCLC patients with the MET amplified is still ongoing. This evidence concerns the gene MET and non-small cell lung carcinoma.